SyntekaBio Inc (226330) - Total Liabilities
Based on the latest financial reports, SyntekaBio Inc (226330) has total liabilities worth ₩15.35 Billion KRW (≈ $10.40 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 226330 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
SyntekaBio Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how SyntekaBio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 226330 current and non-current assets.
SyntekaBio Inc Competitors by Total Liabilities
The table below lists competitors of SyntekaBio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Assura PLC
LSE:AGR
|
UK | GBX1.64 Billion |
|
Advanced Connection Corporation Public Company Limited
BK:ACC
|
Thailand | ฿1.42 Billion |
|
Booster Co. Ltd
KQ:008470
|
Korea | ₩21.35 Billion |
|
ENERSIDE ENERGY EO -01
F:9O8
|
Germany | €83.98 Million |
|
Oxford Instruments PLC
LSE:OXIG
|
UK | GBX211.90 Million |
|
Hawthorn Resources Ltd
AU:HAW
|
Australia | AU$1.59 Million |
|
111 Inc
NASDAQ:YI
|
USA | $253.22 Million |
|
Allarity Therapeutics Inc
NASDAQ:ALLR
|
USA | $8.43 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down SyntekaBio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 226330 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SyntekaBio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SyntekaBio Inc (2017–2025)
The table below shows the annual total liabilities of SyntekaBio Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩14.76 Billion ≈ $10.00 Million |
-21.39% |
| 2024-12-31 | ₩18.77 Billion ≈ $12.72 Million |
-13.45% |
| 2023-12-31 | ₩21.69 Billion ≈ $14.70 Million |
-10.48% |
| 2022-12-31 | ₩24.23 Billion ≈ $16.42 Million |
-39.81% |
| 2021-12-31 | ₩40.25 Billion ≈ $27.28 Million |
+1143.18% |
| 2020-12-31 | ₩3.24 Billion ≈ $2.19 Million |
+76.39% |
| 2019-12-31 | ₩1.84 Billion ≈ $1.24 Million |
-82.46% |
| 2018-12-31 | ₩10.47 Billion ≈ $7.09 Million |
+97.70% |
| 2017-12-31 | ₩5.29 Billion ≈ $3.59 Million |
-- |
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more